Cardiovascular

When the heart and blood vessels function poorly, the body receives insufficient oxygen and nutrients. This may manifest as fatigue, shortness of breath, chest pain, reduced physical endurance, and an increased risk of serious complications.

Cell therapy programs for cardiovascular conditions are most commonly considered in cases of:

• ischemic heart disease

• post-myocardial infarction conditions

• chronic heart failure

• circulatory disorders

• vascular damage (atherosclerosis, microcirculatory impairments)

• myocarditis

These conditions are associated with tissue damage and chronic inflammation — areas where cell therapy may serve as a valuable component of comprehensive treatment.

In cardiology programs, we most commonly recommend the use of mesenchymal stromal cells (MSCs):

Donor-derived MSCs from the umbilical cord or placenta
These cells demonstrate high therapeutic potential, pronounced anti-inflammatory and regenerative effects, and are well tolerated by the body.

Autologous stem cells obtained from the patient’s adipose tissue or bone marrow
The quality of these cells may vary depending on the patient’s age and overall health condition.

The cell type and treatment protocol are selected individually following medical evaluation. In complex cases, MSC therapy may be complemented with components derived from umbilical cord blood.

Mesenchymal stromal cells support cardiac recovery not by replacing damaged cells, but by activating the body’s natural regenerative processes.

They reduce inflammation within cardiac tissue, improve blood supply through the formation of new microvessels, stimulate the heart’s own cells to recover, and help limit the formation of scar tissue after injury.

As part of comprehensive treatment, cell therapy may contribute to improved cardiac function, reduced shortness of breath, and increased physical endurance.

Initial positive changes are typically observed within several weeks after the procedure, while the full therapeutic effect develops over 2 to 6 months as regenerative processes become activated.

Patients may gradually experience:

• reduced shortness of breath and fatigue

• increased physical endurance

• stabilization of heart rhythm

• improved overall well-being

• enhanced cardiac tissue recovery

• decreased reliance on medication

The timing and extent of results vary individually and depend on cardiac condition, disease stage, and the patient’s overall health status.